Abstract: An Numb protein expression inhibitor comprising, as active ingredient, Musashi protein, a polypeptide having an amino acid sequence obtained by replacement, deletion, addition or insertion of at least one amino acid in an amino acid sequence of Musashi protein, or a gene encoding said polypeptide. By the present invention, a new function of Musashi protein has been elucidated. Described specifically, Musashi protein inhibits expression of Numb protein having a neuronal differentiation regulating function and potentiates the activity of the Notch signaling system, so that Musashi protein can be used as a therapeutic for various diseases of the central nervous system.

Abstract: An intracellular calcium concentration increase inhibitor containing as the active ingredient (1) a boron compound represented by the formula (I). The compound represented by the formula (I) inhibits the increase of the intracellular calcium concentration, and therefore it is deemed to be useful as an agent for the prophylaxis and/or treatment of platelet aggregation, ischemic diseases in hearts and brains, immune deficiency diseases, allorgosis, bronchial asthma, hypertension, cerebrovascular spasm, various renal diseases, pancreatitis, Alzheimer's disease, etc.

Abstract: Analysis of substance capable of binding with inositol-1,4,5-triphosphate (IP3) receptor (IP3R), preferably with a regulation domain of IP3R; analysis of the function of IP3R; and establishing of a method of treatment or diagnosis for various malfunctions and diseases associated with IP3R. In particular, control of the activity of intracellular Ca2+ release. More specifically, a regulator for the activity of inositol-1,4,5-triphosphate (IP3) receptor (IP3R), comprised of carbonic anhydrase related protein (CARP); a control agent for intracellular calsium release, comprised of carbonic anhydrase related protein (CARP); and a method of control therewith.

Abstract: The present invention provides a high affinity polypeptide having a binding activity to inositol 1,4,5-trisphosphate, to a gene encoding the polypeptide, to a recombinant vector including the gene, to a transformant including the vector and to a method for producing the high affinity polypeptide having a binding activity to inositol 1,4,5-trisphosphate.

Abstract: The present invention provides Synaptotagmin-binding and yet RNA-binding proteins and genes encoding the proteins. The invention relates to a recombinant protein selected from the group consisting of the following (a) and (b), as well as a gene encoding the protein: (a) a protein comprising the amino acid sequence as shown in SEQ ID NO: 2 (b) a protein which comprises the amino acid sequence as shown in SEQ ID NO: 2 having deletion, substitution or addition of one or several amino acids and which has RNA binding activity.

Abstract: A molecular entity for controlling a calcium according to a first aspect of the invention is (a) an amino acid sequence shown in an amino acid sequence number 1-406 of SEQ ID NO: 1 or (b) an amino acid sequence wherein a part of the amino acid sequence of the amino acid sequence number 1-406 of SEQ ID NO: 1 is deleted, substituted or added.

Abstract: An object of the present invention is to provide a composition, a method, a use thereof, or the like for promoting the development of a mammalian nervous system. The present invention provides a composition for promoting the development of a mammalian nervous system, comprising a fatty acid-binding protein (FABP) fraction as an active ingredient, a method for promoting the development of a mammalian nervous system, comprising administering the FABP fraction to a mammal, a use of the FABP fraction for producing a composition for promoting the development of a nervous system, and the like.

Abstract: The present invention provides a novel IP3 receptor-binding protein that is used as an indicator effective for detecting and quantifying IP3, and a method for detecting and/or quantifying IP3 using the same. Determined is an IP3 receptor-binding protein, particularly a novel IP3 receptor-binding protein, IRBIT, which interacts with an IP3 receptor, and whose interaction is regulated by IP3. IRBIT has the characteristic that it can be dissociated from the IP3 receptor by IP3 at a physiological concentration. Because of this characteristic, IRBIT can be useful as an indicator for detecting IP3 by the FRET method or the like.

Abstract: The present invention relates to neurogenesis inducing genes. In particular, the present invention provides neurogenesis inducing genes coding for Zic proteins, vectors containing such genes, host cells containing such vectors, proteins produced by such host cells, antibodies raised to such proteins, and therapeutic agents or agents for gene therapy for nervous diseases.

Abstract: An intracellular calcium concentration increase inhibitor containing as the active ingredient (1) a boron compound represented by the formula (I).

Abstract: The present invention provides Synaptotagmin-binding and yet RNA-binding proteins and genes encoding the proteins. The invention relates to a recombinant protein selected from the group consisting of the following (a) and (b), as well as a gene encoding the protein: (a) a protein comprising the amino acid sequence as shown in SEQ ID NO: 2 (b) a protein which comprises the amino acid sequence as shown in SEQ ID NO: 2 having delection, substitution or addition of one or several amino acids and which has RNA binding activity.

Abstract: An Numb protein expression inhibitor comprising, as active ingredient, Musashi protein, a polypeptide having an amino acid sequence obtained by replacement, deletion, addition or insertion of at least one amino acid in an amino acid sequence of Musashi protein, or a gene encoding said polypeptide.

Abstract: The present invention provides a truncated Reelin protein containing a F-spondin domain and a CR-50 recognition site but containing no repeat site of a Reelin protein, and a DNA encoding the truncated Reelin protein. The truncated Reelin protein and the DNA encoding this protein of the present invention can be utilized for treatment of diseases including agyria due to abnormal alignment of neurons.

Abstract: The present invention relates to neurogenesis inducing genes. In particular, the present invention provides neurogenesis inducing genes coding for Zic proteins, vectors containing such genes, host cells containing such vectors, proteins produced by such host cells, antibodies raised to such proteins, and therapeutic agents or agents for gene therapy for nervous diseases.

Abstract: The present invention provides a high affinity polypeptide having a binding activity to inositol 1,4,5-trisphosphate, to a gene encoding the polypeptide, to a recombinant vector including the gene, to a transformant including the vector and to a method for producing the high affinity polypeptide having a binding activity to inositol 1,4,5-trisphosphate.

Abstract: The present invention relates to neurogenesis inducing genes. In particular, the present invention provides neurogenesis inducing genes coding for Zic proteins, vectors containing such genes, host cells containing such vectors, proteins produced by such host cells, antibodies raised to such proteins, and therapeutic agents or agents for gene therapy for nervous diseases.

Abstract: The present invention provides a high affinity polypeptide having a binding activity to inositol 1,4,5-trisphosphate, to a gene encoding the polypeptide, to a recombinant vector including the gene, to a transformant including the vector and to a method for producing the high affinity polypeptide having a binding activity to inositol 1,4,5-trisphosphate.

Abstract: Reelin protein itself is further studied for its functions in vertebrates to achieve appropriate diagnosis and treatment of brain disorders resulting from an abnormal reelin gene and abnormally positioned neurons. The present invention provides an epitope region polypeptide of Reelin protein, which comprises a CR-50 antibody recognition site of Reelin protein, but comprises neither a F-spondin domain nor a repeat site; as well as a polynucleotide encoding the polypeptide.

Abstract: The present invention provides Synaptotagmin-binding and yet RNA-binding proteins and genes encoding the proteins.

Abstract: A neurogenesis inducing gene coding for the following protein (a) or (b): (a) a protein consisting of the amino acid sequence shown in SEQ ID NO: 2 (b) a protein which consists of the amino acid sequence shown in SEQ ID NO: 2 having deletion, substitution or addition of at least one amino acid and which has neurogenesis inducing activity.